title: Oliguria during hydrocortisone dosage wean in very low birth weight infants.
abstract: BACKGROUND
  Intravenous hydrocortisone (HC) is often used in very low birth weight infants (VLBW) but can be complicated by oliguria when discontinued or tapered.
  
  
  OBJECTIVE
  To determine which factors were associated with oliguria during HC taper.
  
  
  METHODS
  We reviewed all VLBW infants who received initial doses of HC ≥ 1 mg/kg/d. The initial dose and duration of HC, and the incidence of oliguria (urine output [UO] < 2 mL/kg/h) during HC taper, were recorded. In those with oliguria, we recorded the change in UO (mL/kg/h), blood pressure, and creatinine.
  
  
  RESULTS
  The mean initial HC dose was 2.8 ± 1 mg/kg/d, and the mean total duration of HC therapy was 23 ± 25 days. Oliguria occurred in 24% (13/54) of treated infants. These infants were exposed to higher and longer duration of the initial HC dose than infants without oliguria. Oliguria was predicted by the initial HC dose (odds ratio [OR] 5.8, 95% confidence interval [CI] 1.3-25.8, p = 0.02) and by the number of days at initial dose (OR 1.7, 95%CI 1.1-2.7, p = 0.03).
  
  
  CONCLUSIONS
  Oliguria during HC dosage weaning was associated with higher initial HC exposure.
authors.affiliation: Division of Neonatology, Department of Pediatrics, University of California San Diego, San Diego, California.
authors.forename: J B
authors.initials: JB
authors.lastname: Sauberan
authors.affiliation: Division of Neonatology, Department of Pediatrics, University of California San Diego, San Diego, California.
authors.forename: E M
authors.initials: EM
authors.lastname: Reed
authors.affiliation: Division of Neonatology, Department of Pediatrics, University of California San Diego, San Diego, California.
authors.forename: Y V
authors.initials: YV
authors.lastname: Vaucher
authors.affiliation: Division of Neonatology, Department of Pediatrics, University of California San Diego, San Diego, California.
authors.forename: A C
authors.initials: AC
authors.lastname: Katheria
mesh_terms: D000309:Adrenal Insufficiency / Q000139:chemically induced*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000009:adverse effects*; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D007363:Intensive Care Units, Neonatal; D008297:Male; D009846:Oliguria / Q000139:chemically induced*; D012189:Retrospective Studies; D013375:Substance Withdrawal Syndrome / Q000209:etiology*
chemical_list: D000893:Anti-Inflammatory Agents; D006854:Hydrocortisone